Pyoluteorin

For research use only. Not for therapeutic Use.

  • CAT Number: R021845
  • CAS Number: 25683-07-2
  • Molecular Formula: C11H7Cl2NO3
  • Molecular Weight: 272.08
  • Purity: ≥95%
Inquiry Now

Pyoluteorin is an antibiotic that inhibits Oomycete fungi, including the plant pathogen Pythium ultimum, and suppresses plant diseases caused by this fungus[1]. Pyoluteorin induces human triple-negative breast cancer MDA-MB-231 cells apoptosis in vitro. Pyoluteorin can be used for the research of human triple-negative breast cancer[2].
Pyoluteorin is an antifungal compound composed of a bichlorinated pyrrole linked to a resorcinol moiety, were identified within a 24-kb genomic region of Pseudomonas fluorescens Pf-5[1].
Pyoluteorin has significant cytotoxicity towards MCF-7 (IC50=1.84 μM). Pyoluteorin also displays significantly selective cytotoxicity against BT474, HCC1954, MAD-MB-468, MDA-MB-231, and MCF-10A cells with IC50s of 9.75±0.16, 0.94±0.01, 3.89±0.08, 0.97±0.01, and 57.01±0.76 μM, respectively[2].
Pyoluteorin (0.1-10 μM; for 24 hours) induces change of apoptosis-related protein expressions. Pyoluteorin-induced cell apoptosis in MDA-MB-231 is related to Bcl-2 family proteins and caspase cascade[2].
Pyoluteorin (0.1-10 μM; for 24 h) induces cell cycle arrest and apoptosis in human triple-negative breast cancer cells MDA-MB-231[2].


Catalog Number R021845
CAS Number 25683-07-2
Synonyms

(4,5-dichloro-1H-pyrrol-2-yl)-(2,6-dihydroxyphenyl)methanone

Molecular Formula C11H7Cl2NO3
Purity ≥95%
InChI InChI=1S/C11H7Cl2NO3/c12-5-4-6(14-11(5)13)10(17)9-7(15)2-1-3-8(9)16/h1-4,14-16H
InChIKey JPGWTZORMBTNMF-UHFFFAOYSA-N
SMILES C1=CC(=C(C(=C1)O)C(=O)C2=CC(=C(N2)Cl)Cl)O
Reference

[1]. B Nowak-Thompson, et al. Characterization of the pyoluteorin biosynthetic gene cluster of Pseudomonas fluorescens Pf-5. J Bacteriol. 1999 Apr;181(7):2166-74.
 [Content Brief]

[2]. Ting Ding, et al. Pyoluteorin induces cell cycle arrest and apoptosis in human triple-negative breast cancer cells MDA-MB-231. J Pharm Pharmacol. 2020 Jul;72(7):969-978.
 [Content Brief]

Request a Quote